Abstract
The enlarging HIV/AIDS pandemic and the virus’ ability to develop resistance to anti-retroviral therapy requires the development of new drugs based on novel targets. Viruses interact extensively with the host at the cellular and molecular levels, which is necessary for the expression of viral proteins and replication of viral genomes. At another level, these interactions also help the virus evade host immune responses. Besides the prototypic retroviral proteins (Gag, Pol and Env), HIV-1 also expresses two regulatory proteins (Tat and Rev) and four accessory proteins (Nef, Vif, Vpr and Vpu). The accessory proteins are not required for viral replication in vitro, but are critical for pathogenesis and disease development in the host. We have focused our efforts on two of these – Nef and Vpu, with an aim to understand their interactions with host proteins and the functional consequences of these interactions for HIV-1 infection and pathogenesis. The Nef protein binds to multiple host proteins to optimize the host cell environment and to enable infected cells to evade the host immune response. A major property of Nef is to downregulate surface expression of the CD4, MHC I and MHC II proteins, by increasing the endocytosis of these molecules. We also discovered that Nef binds to the cytoplasmic domains of the B7 family of costimulatory proteins – CD80 and CD86; this results in their removal from the cell surface and sequestration to the Golgi compartment (1-3). We have now developed an in vitro screen based on purified recombinant Nef proteins and a 20-mer synthetic peptide from the cytoplasmic domain of CD80 and CD86. A chemical library comprising of 1064 compounds was screened and ~7% compounds were obtained as hits, which inhibited the Nef-CD80/CD86 interaction. These compounds are now being evaluated in a cellbased assay and an independent dose dependent response assay. The top hits will be used in a combinatorial chemical approach to synthesize a large array of new molecules for further screening using the in vitro and cell-based screens. The HIV-1 Vpu protein is required for the release of new virions from the surface of infected cells; for this the transmembrane domain of Vpu is critical. Using the Topology Data Bank of Transmembrane Proteins (TOPDB) database we extracted 13 alpha-helical sequences that closely resemble the Vpu-TM domain. We have taken the top two hits and have constructed recombinant Vpu proteins in which the native TM domain was replaced by the identified sequences. These recombinant proteins were successfully expressed in HEK293 cells, and are now being tested for their effects on virion release as well as their ability to inhibit Vpu activity. We describe here two paradigms to screen for anti-HIV activity based on proteinprotein interactions. Results will be presented for both of these.